Peginterferon beta-1a (Peginterferon beta-1a) is the first pegylated interferon beta-1a molecule. Peginterferon beta-1a causes apoptosis in cancer cells and displays anticancer effect in nude mouse models. Peginterferon beta-1a may be used in cancer and multiple sclerosis (RMS) research.

Physicochemical Properties

CAS #	1211327-92-2
Appearance	Typically exists as solid at room temperature
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	Peginterferon beta-1a (0.001-1000 ng/mL; 5 d) has an impact on the viability of tumor cells, including SK-MEL-2, SK-MEL-5, MeWo, and WM-266-4[1]. Cell apoptosis is induced by peginterferon beta-1a at concentrations of 10, 100, and 1,000 ng/mL[1].
ln Vivo	In xenografts of nude mice, peginterferon beta-1a (0.1–1.6 mg/kg; sc QW/BIW/TIW for 3–4 weeks) suppresses the growth of melanoma cancers A-375, SK-MEL-1, and WM-266-4[1].
Cell Assay	Cell Viability Assay[1] Cell Types: SK -MEL-1, SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cell lines Tested Concentrations: 0.001-1000 ng/mL Incubation Duration: 5 d Experimental Results: Inhibited the cell viability of SK-MEL -2, SK-MEL-5, MeWo and WM-266-4 tumor cells and demonstrated an IC50 value of 2-3 ng/mL to WM-266-4 cells. Western Blot Analysis[1] Cell Types: WM-266 -4 cell line Tested Concentrations: 10, 100 and 1000 ng/mL Incubation Duration: 24 h Experimental Results: Induced the cleavage of PARP, caspase-8, and -9, induction of TRAIL and phosphorylation of STAT1.
Animal Protocol	Animal/Disease Models: Nude mice with human SK-MEL-1 and A-375 melanoma xenografts[1] Doses: 0.1-1.6 mg/kg Route of Administration: subcutaneous (sc)injection; once/twice a week; for 3/4 weeks Experimental Results: Dramatically inhibited SK-MEL-1 tumor growth at 0.4 mg/kg (QW; 3 w) and inhibited A-375 melanoma tumors at 1.6 mg/kg (BIW ; 4 w). Animal/Disease Models: Nude mice with human WM-266-4 melanoma xenografts[1] Doses: 0.4-1.6 mg/kg Route of Administration: subcutaneous (sc)injection; 0.4-1.6 mg/kg; once/twice/three times a week for 4 w Experimental Results: The QW dose of 1.6 mg/kg and all doses given BIW and TIW induced tumor regression, with a 1.6 mg/kg QW dose induced significant tumor inhibition relative to 0.8 mg/kg QW.
References	[1]. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models. J Interferon Cytokine Res. 2017 Jan;37(1):20-31.

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)